Amgen Inc.
Amgen Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Thousand Oaks, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $37 billion and a profit of $7.7 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2836, Biological Products, (No Diagnostic Substances)); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.8 out of ten, 9 of 9 metrics filed: past 7.0 out of ten, present 7.8 out of ten, future 5.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 5.3 out of ten. 1 warning event since 2017; the latest 2026-07-31. 53rd percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 8.0 out of ten. +7.8% a year over 7 filed years; profitable in 7 of 7. 80th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 7.3 out of ten. Share count grew 0.1% a year. 49% of cash flow returned. Insiders: 14 sales, 0 purchases. 73rd percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.8 out of ten. ROE 89%: 89¢ of profit per shareholder dollar. Leverage 90%: owes 90¢ per asset dollar. 68th percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 8.1 out of ten. top 19% of 102 in its family; net margin 21%. 81st percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 9.3 out of ten. top 7% of 108 in its family for leadership; chief executive since 2012. 93rd percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.0 out of ten. bottom 40% of 92 in its family for room to expand. 40th percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 7.3 out of ten. top 27% of 100 in its family for growth drivers. 73rd percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 4.8 out of ten. bottom 48% of 72 in its family for expectations against reality. 48th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-13 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-04 (on EDGAR). Newest filing: Form 3, 2026-09-04. Filings on record since 1994. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Other Products 20%, Prolia 12%, Repatha 8%, Otezla 6%, Enbrel 6%, EVENITY 6%. By geography: United States 72%, Outside the United States 28%. As tagged in its annual report (Form 10-K, filed 2026-02-13).
Who runs it
Bradway, Robert A (Chairman, CEO and President); Dittrich, Thomas J.w. (EVP & CFO); Griffith, Peter H. (EVP & CFO); Reese, David M (EVP & Chief Technology Officer); Khosla, Rachna (SVP, Business Development); Busch, Matthew C. (VP, Finance & CAO); Grygiel, Nancy A. (SVP & CCO); Miller, Derek (SVP, Human Resources); Bradner, James E. (EVP, Research and Development); Gordon, Murdo (EVP, Global Commercial Ops); and 13 more. 23 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.